UCL and Francis Crick-founded Achilles has secured $69.9m in its series C round.
Achilles Therapeutics, a UK-based cancer immunotherapy developer spun out from University College London and Francis Crick Institute, secured £52.7m ($69.9m) in a series C round today backed by Syncona.
OrbiMed, Boxer Capital of Tavistock Group, RA Capital Management, Forbion, Invus, Perceptive Advisors and Redmile Group as well as unnamed investors backed the round.
Achilles is working on personalised T cell cancer therapies.
The series C financing will accelerate research and development activities and allow Achilles to expand its clinical network to support ongoing phase 1/2 trials. The money will also enable Achilles to build out manufacturing capabilities and expand its preclinical pipeline.
RA Capital led a $120m series B round in 2019, when Syncona, Forbion, Perceptive Advisors, Redmile and Invus also took part.
Achilles was launched in 2016 with $16.8m of funding from Syncona and Cancer Research Technology, the tech transfer arm of research charity Cancer Research UK.
